Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?
Authors
Keywords
-
Journal
Therapeutic Advances in Gastroenterology
Volume 6, Issue 1, Pages 15-31
Publisher
SAGE Publications
Online
2012-07-10
DOI
10.1177/1756283x12453636
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.
- (2017) I. Chau et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer.
- (2017) M. Alsina et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
- (2017) Tom Samuel Waddell et al. JOURNAL OF CLINICAL ONCOLOGY
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Multidimensional Identification of Tissue Biomarkers of Gastric Cancer
- (2012) Tiannan Guo et al. JOURNAL OF PROTEOME RESEARCH
- Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?
- (2012) H. Wong et al. ONCOLOGIST
- MET Expression and Amplification in Patients with Localized Gastric Cancer
- (2011) Y. Y. Janjigian et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
- (2011) Hyun-Jin Nam et al. CANCER LETTERS
- Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [ 18 F]FLT Uptake
- (2011) Thorsten Fuereder et al. CLINICAL CANCER RESEARCH
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- Molecular Classification of Gastric Cancer: A New Paradigm
- (2011) M. A. Shah et al. CLINICAL CANCER RESEARCH
- Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
- (2011) Yu Kataoka et al. INVESTIGATIONAL NEW DRUGS
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
- (2011) H.-J. Nam et al. MOLECULAR CANCER THERAPEUTICS
- Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer
- (2011) Ozgur Kemik WORLD JOURNAL OF GASTROENTEROLOGY
- Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
- (2010) S. Rao et al. ANNALS OF ONCOLOGY
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
- (2010) Da-zhi Xu et al. BMC CANCER
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2010) F Lordick et al. BRITISH JOURNAL OF CANCER
- Comparative Enzyme Immunoassay of Matrix Metalloproteinases-2, -7, -9 and Their Tissue Inhibitor-2 in Tumors and Plasma of Patients with Gastric Cancer
- (2010) E. S. Gerstein et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- Genetic profiles of gastroesophageal cancer: combined analysis using expression array and tiling array–comparative genomic hybridization
- (2010) Anna Isinger-Ekstrand et al. CANCER GENETICS AND CYTOGENETICS
- RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
- (2010) Kyung-Hun Lee et al. CANCER LETTERS
- Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
- (2010) Z. A. Wainberg et al. CLINICAL CANCER RESEARCH
- Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts
- (2010) W.-m. Zhao et al. CLINICAL CANCER RESEARCH
- Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination
- (2010) Fumiko Taguchi et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
- (2010) Weijing Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma
- (2010) Ming Zhang et al. JOURNAL OF SURGICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer
- (2010) Yongning Zhou et al. TUMOR BIOLOGY
- Status of PI3K inhibition and biomarker development in cancer therapeutics
- (2009) B. Markman et al. ANNALS OF ONCOLOGY
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
- (2009) S-W Han et al. BRITISH JOURNAL OF CANCER
- Relation between outcomes and localisation of p-mTOR expression in gastric cancer
- (2009) T Murayama et al. BRITISH JOURNAL OF CANCER
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
- (2009) C Pinto et al. BRITISH JOURNAL OF CANCER
- Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients
- (2009) Sook Ryun Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Hereditary diffuse gastric cancer: A manifestation of lost cell polarity
- (2009) Bostjan Humar et al. CANCER SCIENCE
- Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer
- (2009) Taro Matsuzaki et al. CANCER SCIENCE
- Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer
- (2009) G. Yu et al. CLINICAL CANCER RESEARCH
- A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
- (2009) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Molecular basis of therapeutic approaches to gastric cancer
- (2009) Kaichun Wu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
- (2009) Nicola Normanno et al. Nature Reviews Clinical Oncology
- Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice
- (2009) Chun-Gen Xing et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
- (2009) Xiu Li Zhang et al. WORLD JOURNAL OF SURGERY
- Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer
- (2009) Chia Huey Ooi et al. PLoS Genetics
- Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
- (2008) J Matsubara et al. BRITISH JOURNAL OF CANCER
- FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
- (2008) K. Kunii et al. CANCER RESEARCH
- Molecular cancer therapy: Can our expectation be MET?
- (2008) Cristina Migliore et al. EUROPEAN JOURNAL OF CANCER
- EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number
- (2008) M A Kim et al. HISTOPATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More